RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (October 2016)

41 slides from RespireRx Pharmaceuticals's investor presentation, Oct 17, 2016

  1. Slide 1: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements A) The matters discussed in this presentation that are not historical facts are "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that such forward-looking stat

  3. Slide 3: Breath quote

    Breath GQ RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." — Abbot George Burke

  4. Slide 4: Company Focus

    Company Focus Gd RespireRx o Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) o Drug-induced Respiratory Depression (RD) - Ampakines = Acute use — surgical anesthesia/sedation = Semi-acute use — post-surgical pain management with opioids = Chronic

  5. Slide 5: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases Gd Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 development programs o Additional pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent applicati

  6. Slide 6: Respiratory Diseases Product Pipeline

    RespireRx Pharmaceuticals Inc Respiratory Diseases Product Pipeline Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea T_—_————<<<, Cental Soep Apnea — a? CX1739 Opioit.nduced RO _——p Spinal Cord Injury —7 CX717 Opioid-induced RD —————, Cx1942 Drug-induced RD. rae =)

  7. Slide 7: Dronabinol for Obstructive Sleep Apnea

    Dronabinol for Obstructive Sleep Apnea Pharmaceuticals Inc

  8. Slide 8: Obstructive Sleep Apnea

    Obstructive Sleep Apnea Ad RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed o The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sl

  9. Slide 9: Completed Phase 2A Trial of Dronabinol in OSA

    Completed Phase 2A Trial of Dronabinol in OSA Gd RespireRx o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days = 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polysomnogram (PSG) at bas

  10. Slide 10: Dronabinol: Breakthrough Treatment for OSA

    Dronabinol: Breakthrough Treatment for OSA Gd Resp pireRx Pharmaceuticals Inc o Mechanism of Action = Dronabinol is (delta 9) THC, a cannabinoid agonist o Background = Schedule III drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients

  11. Slide 11: Dronabinol Proven to Reduce Apnea in OSA Subjects

    Dronabinol Proven to Reduce Apnea in OSA Subjects Apnea/Hypopnia Index (AHI) % change from baseline 40% 30% 20% 10% 0% 10% 20% 30% 40% P=0.17 Placebo Dronabinol RespireRx Pharmaceuticals Inc 11

  12. Slide 12: Apnea Suppression as a Function of Dose and Time

    Apnea Suppression as a Function of Dose and Time RN RespireRx nespirek Inc 2 4 4 ; 1st Half a 2nd Half “s n=17 n=13 n=8 ° AAHI versus Baseline 8 5 The plasma half-life of dronabinol is 2 — 4 hours. 12

  13. Slide 13: Completed Dronabinol Phase 2B Clinical Trial in OSA

    Completed Dronabinol Phase 2B Clinical Trial in OSA A)Resp ireRx o Sponsored and led by U of Illinois o 4 major centers, fully funded by NIH o Doses: Placebo, 2.5 mg, 10 mg qd o 6 weeks dosing o Trial completed o Data expected Q4/2016 o Meet with FDA after trial completion to determine registration

  14. Slide 14: The Dronabinol Opportunity

    The Dronabinol Opportunity Ad RespireRx Pharmaceuticals Inc Impact on Patient Commercial Opportunity First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands pre

  15. Slide 15: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market A) RespireRx Pharmaceuticals Inc o Issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics and medical

  16. Slide 16: Ampakines for Opioid-Induced Respiratory Depression

    Ampakines for Opioid- Induced Respiratory Depression 16

  17. Slide 17: Translational Approaches to Respiratory Disorders

    Translational Approaches to Respiratory Disorders — A Short Course AS) F AMPAKINI Voice «$10 Dose CX1739 (mg/kg) IE 100 pA 50ms 2 RespireRx Pharmaceuticals Inc Brain stem nuclei that regulate breathing contain opioid and AMPA glutamate receptors that inhibit and excite, respectively Ampakines act as

  18. Slide 18: CX717 Prevents Opioid-induced Respiratory Depression in Humans

    CX717 Prevents Opioid-induced Respiratory Depression in Humans — Target Engagement RespireRx Pharmaceuticals Inc 16: NS + C— Placebo 5 0X717 12: ™P<0.01 NS - Not Significant Breaths/min o 4 das the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. Oertel et al., (2010) Clin Pharm

  19. Slide 19: CX717 Does Not Interfere With the Analgesic Properties of Opioids

    CX717 Does Not Interfere With the Analgesic Properties of Opioids AQ RespireRx cated atte Inc Analgesia 2.0: [Placebo > 15: @CX717 & 2 a 5 1.0 NS_ 2) i= S o 0.5: Delivery of a electrical stimulation to finger ’ 0.0: Alfentanil reduced the pain sensitivity Baseline +Alfentanil +Naloxone (produced ana

  20. Slide 20: CX1739: A Third Generation, Oral Ampakine

    CX1739: A Third Generation, Oral Ampakine in Phase 2 RespireRx Pharmaceuticals Inc o Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression = Combination formulation with an opioid for treatment of chronic pain o Stage of Development = Suc

  21. Slide 21: CX1739: Phase 2A in Opioid-Induced Respiratory Depression

    ReSPIren Inc CX1739: Phase 2A in Opioid-Induced Respiratory Depression WR RespireRx Antagonism of Remifentanil-Induced Respiratory Depression by CX1739 in Two Frotocol Clinical Models of Respiratory Depression Design Randomized, Blinded, Placebo-controlled, Cross-Over with Dose Escalation Dosing 17

  22. Slide 22: CX1739: Phase 2A Overall Study Design

    CX1739: Phase 2A — Overall Study Design Resp pireRx Pharmaceuticals Inc STAGE 1 STAGE 2 Double-blind, Placebo-Controlled Crossover Open-label, Dose Ascending ox1739 oxt739 300 mg 300 mg Screening _Baseline \ A oxt39 extra0 case marae 600 mg 900 mg Randomize Placebo Placebo Week 1 Week 2 Week 3 Week

  23. Slide 23: CX1739: Phase 2A Daily Protocol

    CX1739: Phase 2A — Daily Protocol RespireRx Pharmaceuticals Inc Placebo REMI 1 — bolus injection REMI 2 —continuous infusion X1739 Model of acute overdose Model of chronic oral use i T 1 0 3.0 3.5 4 hours 23

  24. Slide 24: CX1739: Phase 2A Safety

    CX1739: Phase 2A — Safety CAS) Resp ireRx eet Inc s SAFETY DATA “ T 2 + CX1739 was safe and well tolerated with no SAEs Most frequent AEs were nausea, vomiting, headache and dizziness, all of which are : common side effects of opioids . 39 of 49 AEs occurred after 2 q remifentanil ° ‘| 05 05-1 1-15

  25. Slide 25: Ampakines for Central Sleep Apnea

    Ampakines for Central Sleep Apnea Pharmaceuticals Inc 25

  26. Slide 26: Central Sleep Apnea (CSA)

    Central Sleep Apnea (CSA) A)Resp ireRx o Lack of drive from the brain to breathe during sleep o CSA Patients = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No medicine or device is approved for CSA 26

  27. Slide 27: CX1739: Completed Phase 2A in Sleep Apnea Single Dose

    CX1739: Completed Phase 2A in Sleep Apnea — Single Dose RespireRx Pharmaceuticals Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a si

  28. Slide 28: Patient Selection: CX1739 More Effective in Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas RN RespireRx Pharmaceuticals Inc Obstructive Apneas Mixed Apneas Central Apnea BRS & s Apnea Index (Eventsfhr) eansB a Apnea Index (Eventsfhr) cana aaa Apnea Index (Eventsfhr) on & 2 © Ss e e se ¢ e & & %e , “ly

  29. Slide 29: CX1739: Proposed Phase in Sleep Apnea Multiple Dose

    CX1739: Proposed Phase 2 in Sleep Apnea — Multiple Dose as RespireRx nespire’ Inc Evaluation of CX1739 for the Treatment of Central Sleep Apnea in Patients on Chronic Protocol eee Opioid Therapy + Randomized, Blinded, Placebo-controlled, Multiple Dose Study at Multiple Sites Design * Subjects with a

  30. Slide 30: Ampakines for Breathing Disorders due to Spinal Cord Injury

    Ampakines for Breathing Disorders due To Spinal Cord Injury

  31. Slide 31: CX717: Second Generation Oral Ampakine

    CX717: Second Generation Oral Ampakine in Phase 2 RespireRx Pharmaceuticals Inc o Targeted Indications = Spinal Cord Injury = Combination formulation with an opioid for treatment of chronic pain o Stage of Development = Completed 6 Phase 1 and 4 Phase 2 studies = Two positive Phase 2A trials in opio

  32. Slide 32: CX717: Spinal Cord Injury

    CX717: Spinal Cord Injury RespireRx Pharmaceuticals Inc Incidence * Estimated 276,000 people with SCI in the US, with 12,000 new cases per year + ~92,000 with respiratory distress * Eligible for Orphan Status Breathing problems are substantial after SCI * Approximately half of all SCls occur in the

  33. Slide 33: CX717 Animal Models of Spinal Cord Injury

    CX717 — Animal Models of Spinal Cord Injury RN RespireRx Pharmaceuticals Inc Unilateral hemi-transections at the level of the 2" cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and contribute to the regulation of breathin

  34. Slide 34: CX717: Proposed Phase in Spinal Injury Multiple Dose

    CX717: Proposed Phase 2 in Spinal Injury — Multiple Dose RespireRx Pharmaceuticals Inc Evaluation of CX717 for the Treatment of Breathing Disorder in Patients with Protocol scl Design Ascending Dose Study Dosing BID doses of 250 mg, 500mg and 750 mg CX717 daily for 28 days Primary: Study To evaluate

  35. Slide 35: Summary

    Summary a: Pharmaceuticals Inc 35

  36. Slide 36: Respiratory Diseases Product Pipeline

    RespireRx Pharmaceuticals Inc Respiratory Diseases Product Pipeline Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea T_—_————<<<, Cental Soep Apnea — a? CX1739 Opioit.nduced RO _——p Spinal Cord Injury —7 CX717 Opioid-induced RD —————, Cx1942 Drug-induced RD. rae =)

  37. Slide 37: Development Milestones

    Development Milestones Resp pireRx Pharmaceuticals Inc 4Q2016 | 1Q2017 | 2Q2017 | 3Q2017 | 4Q2017 | 1Q2018 CX1739 RD Clinical Trial at Duke CSA Clinical Trial pending results of RD Trial Formulation, PK and ADME CX717 FDA Regulatory Spinal Cord Injury Clinical Trial Ampakine/Opiate Combination Formu

  38. Slide 38: Capital Structure & Market Metrics

    Capital Structure (rounded) & Market Metrics RN RespireRx Total as of October 13, 2016 Common Stock 2,019,000 Common Stock Equivalents of Convertible Notes (estimated) 29,000 Common Stock Equivalents of all Options and Warrants Granted (excludes 371,000 reserved for equity plans) 1,745,000 Total 3,7

  39. Slide 39: Management and Directors

    Management and Directors James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director Senior VP, Napo Pharmaceuticals Direc

  40. Slide 40: Innovative Medicines for Respiratory Diseases

    Innovative Medicines for Respiratory Diseases Gd Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 development programs o Additional pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent applicati

  41. Slide 41: Medicines for Respiratory Diseases

    Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases

RespireRx Pharmaceuticals — Investor Presentation (October 2016) on 6ix